BMW North America is marking its 50th anniversary at the 73rd edition of the Twelve Hours of Sebring on March 15, with the ...

Though horsepower may never be the same with the electrification of the auto industry, BMW has made some truly powerful ...

and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...

Learn More CSL Ltd (ASX: CSL) shares are up 0.3% at $261.87 today, shaking off the broader market sell-down. This sees the company with a market cap of almost $127 billion, making it the third ...

Historically, BMW coupés have simply been swoopier, less practical versions of their saloon car counterparts. Not any more – the BMW 4 Series is a rakish model in its own right. Sure ...

CSL Limited (CSL), an ASX-listed company, is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines. CSL's ...

While otherwise robust, CSL half-year results last Wednesday revealed the impact of an “alarming” fall off in influenza vaccination rates, especially in the US. CEO Paul McKenzie attributes the ...

Last November, I strapped into the rear passenger seat of an all-electric, four-door sedan with BMW test driver and 24-hour racer Jens Klingmann behind the wheel. It was a cold day at BMW’s ...

CSL Limited (ASX:CSL) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the week after its latest half-year results. Revenues of US$8.5b were in line ...

CSL has a portfolio that includes treatments for haemophilia and immune deficiencies, and influenza vaccines. Credit: © 2023 CSL, All Rights Reserved. CSL has ...

ASX health stocks fell 3.78% over the past week, while the broader market edged up 0.77% Australia’s biggest health care name CSL weighed on sector with soft H1 FY25 result Shares of merged Chemist ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market expectations Behring and Vifor outperformed, while Seqirus underperformed due to ...